NRX Pharmaceuticals Inc (NASDAQ:NRXP)’s traded shares stood at 0.36 million during the last session, with the company’s beta value hitting 1.57.The NRXP share’s 52-week high remains $6.01, putting it -74.71% down since that peak but still an impressive 68.02% since price per share fell to its 52-week low of $1.10.
Analysts have given a consensus recommendation of Buy for NRX Pharmaceuticals Inc (NRXP), translating to a mean rating of 1.00. Of 1 analyst(s) looking at the stock, 0 analyst(s) give NRXP a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 1 recommend it as a Buy.
NRX Pharmaceuticals Inc (NASDAQ:NRXP) trade information
The 5-day price performance for the stock is 5.20%, and 51.54% over 30 days. With these gigs, the year-to-date price performance is 56.36%.
The extremes give us $2 and $2 for target low and target high price respectively. As such, NRXP has been trading 41.86% off suggested target high and 41.86% from its likely low.
NRXP Dividends
NRX Pharmaceuticals Inc has its next earnings report out in July. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
We also have AdvisorShares Trust-AdvisorShares Psychedelics ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the NRX Pharmaceuticals Inc (NRXP) shares. Going by data provided on Apr 30, 2025 , AdvisorShares Trust-AdvisorShares Psychedelics ETF holds roughly 297.8 shares. This is just over 1.72% of the total shares, with a market valuation of $1.02 million. Data from the same date shows that the other fund manager holds a little less at 251.76, or 1.46% of the shares, all valued at about 0.87 million.
